z-logo
open-access-imgOpen Access
Caffeine yields aneuploidy through asymmetrical cell division caused by misalignment of chromosomes
Author(s) -
Katsuki Yoko,
Nakada Shinichiro,
Yokoyama Tetsuji,
Imoto Issei,
Inazawa Johji,
Nagasawa Masayuki,
Mizutani Shuki
Publication year - 2008
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2008.00862.x
Subject(s) - aneuploidy , mad2 , mitosis , prometaphase , caffeine , metaphase , biology , spindle checkpoint , cell division , chromosome instability , cell , microbiology and biotechnology , cell cycle , chromosome , genetics , spindle apparatus , endocrinology , gene
Aneuploidy has been implicated as an important step leading to various neoplasias. Although genetic factors that block aneuploidy have been the subject of intense interest, the impact of pharmacological and environmental substances on the development of aneuploidy has not been studied. Here, we show that caffeine induces aneuploidy through asymmetrical cell division. Mitotic exits of HeLa, U2OS, and primary fibroblast cells were significantly delayed by 10 mmol/L caffeine. Most caffeine‐treated mitotic cells showed misalignment of chromosomes at the metaphase plates, and were arrested at prometaphase. Mitoticarrest deficient 2 (MAD2) depletion rescued the caffeine‐induced delay of mitotic exit, indicating that caffeine‐induced prolongation of mitosis was caused by activation of a MAD2‐dependent spindle checkpoint. Enumeration of centromeres by fluorescence in situ hybridization revealed that cell division in the presence of caffeine was not symmetrical and resulted in aneuploid cell production. Most of these cells survived and underwent DNA synthesis. Our findings reveal a novel pharmacological effect of a high concentration of caffeine on genomic stability in dividing cells. ( Cancer Sci 2008; 99: 1539–1545)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here